Lipopolysaccharide Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against Decapentaplegic, and CCAAT/Enhancer‐Binding Protein C/EBP Transcription Factors

Akanksha Sharma, Alok K. Verma, Matthew Kofron, Ramesh Kudira, Alexander Miethke, Tong Wu, Jiang Wang, Chandrashekhar R. Gandhi – 16 February 2020

Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy

Alessandro Vitale, Franco Trevisani, Fabio Farinati, Umberto Cillo – 16 February 2020 – Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The “stage hierarchy” approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West.

Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity

Ekaterina Smirnova, Puneet Puri, Mark D. Muthiah, Kalyani Daitya, Robert Brown, Naga Chalasani, Suthat Liangpunsakul, Vijay H. Shah, Kayla Gelow, Mohammed S. Siddiqui, Sherry Boyett, Faridoddin Mirshahi, Masoumeh Sikaroodi, Patrick Gillevet, Arun J. Sanyal – 14 February 2020

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Johann Felden, Augusto Villanueva – 14 February 2020 – Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted within Milan criteria have outstanding outcomes with a 5‐ and 10‐year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor.

Lifestyle Modification Leads to Spatially Variable Reduction in Hepatic Steatosis in Potential Living Liver Donors

Hyo Jung Park, Kyoung Won Kim, Jae Hyun Kwon, Jeongjin Lee, Taeyong Park, Heon‐Ju Kwon, Gi‐Won Song, Sung‐Gyu Lee – 14 February 2020 – The spatial variability of hepatic fat reduction in potential living liver donors with hepatic steatosis (HS) who undergo lifestyle modification has not been investigated. Here, we aimed to examine the intrasegmental and intersegmental variability of changes in liver attenuation on computed tomography (CT) in potential living liver donors with HS after diet modification and exercise.

Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment Strategies

Maureen Whitsett, David M. Feldman, Ira Jacobson – 14 February 2020 – Hepatitis E virus (HEV), of the family Herpesviridae, is a virus that infects nearly 20 million people per year throughout the world. HEV is most commonly transmitted via the fecal‐oral route and has long been described as a virus that afflicts only those in resource‐poor countries. However, HEV has been detected in numerous animal carriers, various food sources, and even in human blood products in resource‐rich regions of the world.

Subscribe to